CG
REGN icon

Carmignac Gestion’s Regeneron Pharmaceuticals REGN Stock Holding History

Carmignac Gestion’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114M Buy
182,507
+65,936
+57% +$44.9M 1.48% 17
2026
Q1 		$90M Buy
116,571
+66,600
+133% +$51M 1.38% 20
2025
Q4 		$38.6M Buy
+49,971
New +$33.9M 0.52% 38

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Carmignac Gestion's REGN Position: Q2 2026 in Review

Carmignac Gestion increased its Regeneron Pharmaceuticals (REGN) stake by 57% in Q2 2026, buying an estimated $44.9M and bringing the position to 182,507 shares worth $114M. The position accounts for 1.48% of the portfolio, ranked #17.

Carmignac Gestion first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Carmignac Gestion held 182,507 shares of Regeneron Pharmaceuticals worth $114M as of Q2 2026.
  • Carmignac Gestion bought 65,936 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $44.9M.
  • Regeneron Pharmaceuticals made up 1.48% of Carmignac Gestion's portfolio in Q2 2026, its #17 holding.
  • Carmignac Gestion first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Carmignac Gestion's 13F filing for Q2 2026, filed 13 Aug 2026.